Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Centessa Pharmaceuticals (CNTA) Operating Expenses: 2022-2025

Historic Operating Expenses for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $53.8 million.

  • Centessa Pharmaceuticals' Operating Expenses rose 15.91% to $53.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $228.8 million, marking a year-over-year increase of 35.78%. This contributed to the annual value of $201.1 million for FY2024, which is 12.87% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Operating Expenses of $53.8 million as of Q3 2025, which was down 1.58% from $54.7 million recorded in Q2 2025.
  • Over the past 5 years, Centessa Pharmaceuticals' Operating Expenses peaked at $74.6 million during Q4 2024, and registered a low of $36.1 million during Q1 2024.
  • Moreover, its 3-year median value for Operating Expenses was $46.4 million (2024), whereas its average is $48.5 million.
  • Per our database at Business Quant, Centessa Pharmaceuticals' Operating Expenses plummeted by 31.27% in 2023 and then surged by 77.44% in 2024.
  • Quarterly analysis of 4 years shows Centessa Pharmaceuticals' Operating Expenses stood at $41.6 million in 2022, then climbed by 1.03% to $42.0 million in 2023, then surged by 77.44% to $74.6 million in 2024, then rose by 15.91% to $53.8 million in 2025.
  • Its Operating Expenses stands at $53.8 million for Q3 2025, versus $54.7 million for Q2 2025 and $45.8 million for Q1 2025.